Kanishk Kumar on 2034 Forecasts for aHUS Associated Thrombotic Microangiopathy
Kanishk Kumar, Digital Marketing Executive at DelveInsight Business Research LLP, shared on LinkedIn:
”Atypical Hemolytic Uremic Syndrome Market 2034: Targeting Complement-Mediated Thrombotic Microangiopathy
Atypical Hemolytic Uremic Syndrome (aHUS), a rare thrombotic microangiopathy caused by uncontrolled complement activation, is advancing with novel C5 inhibitors and factor B blockers in 2034.
Delve Insight‘s report covers epidemiology in the 7MM (US, EU4, UK, Japan), market dynamics, and forecasts, projecting significant CAGR from 2020-2034, with ~4,800 diagnosed cases in 7MM in 2023, ~3,500 in US, and adolescents/adults representing ~80% of cases.
Key Developments in aHUS Market:
December 11, 2025: Novartis launched a Phase 3 study of iptacopan in treatment-naive aHUS patients.
December 8, 2025: Alexion Pharmaceuticals, Inc. disclosed a Phase 3b study of eculizumab in Chinese aHUS patients.
Leading Atypical Hemolytic Uremic Syndrome Companies include Novartis, Hoffmann-La Roche, Chugai Pharmaceutical Co., Ltd., Alexion Pharmaceuticals, Inc. , and others.
Promising therapies include Eculizumab, Crovalimab, Iptacopan, NM8074, Ravulizumab, ULTOMIRIS, SOLIRIS, and others.
Delve Insight’s comprehensive report on Atypical Hemolytic Uremic Syndrome Market Insights, Epidemiology and Market Forecast – 2034”
Find the full report here.
Read the full post.
Stay updated with Hemostasis Today.
-
Jan 8, 2026, 05:51Dominika Jędrzejewska Akbaş Links Sleep Deprivation, Obesity, and Stroke
-
Jan 8, 2026, 05:42Rob Maloney: A Bruise that Did Not Go Away…
-
Jan 8, 2026, 05:33Matías J Alet on Treating Early Neurological Deterioration in Lacunar Stroke
-
Jan 8, 2026, 05:11Thomas Meinel Shares The English Stroke Guidelines 2026
-
Jan 8, 2026, 05:03Hilla Ben-Pazi: We Were Pleased to Receive a Grant from the Israeli Ministry of Economy
-
Jan 8, 2026, 04:24Nikhil Agrawal Breaks Down Perioperative Anticoagulation
-
Jan 8, 2026, 03:58Louise St Germain Bannon Appointed Interim Executive Director of ISTH
-
Jan 8, 2026, 03:47Wolfgang Miesbach on Fernando Corrales-Medina’s Team’s Latest Cross-Sectional Study on Haemophilia
-
Jan 8, 2026, 03:28Rick Matthews: Powerful Perspective from Erin and the NBCA Team